Janice MacLennan, Founder & CEO, Nmblr, explains why biopharma companies hoping to enter the competitive GLP-1 market need to build value narratives in parallel with scientific evidence.  The emergence of GLP-1 therapies is unprecedented, with the global GLP-1 receptor agonist market valued at $66.4 billion in 2025 and projected to reach $185.3 billion by 20331. This trajectory is set to continue. Morgan Stanley estimates the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!